Introduction: Epidermal growth factor receptor inhibitors, including panitumumab, are drugs with a proven effect on overal survival of patients with advanced colorectal cancer. They have a better safety profile compared to classic cytotoxic drugs, but they may have side effects resulting directly from the drug's mechanism of action. Case report: A 64-year-old man, treated palliatively with panitumumab for cancer of the sigmoido-rectal junction, was admitted to the Dermatology Department with disseminated maculopustular rash on the scalp and upper trunk. Also, layered yellowish crusts were present on the face and scalp. Edema and erythema were visible in the lateral folds of the nails of the hands and feet. The diagnosis of panitumumab -induced PRIDE syndrome (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors). Laboratory tests showed hypomagnesemia, hyperglycemia and elevated glycated hemoglobin values. Doxycycline and systemic glucocorticosteroids were introduced with improvement. Conclusions: Early diagnosis of the cutaneous adverse effects oncological treatment and initiation of treatment contributes to the improvement of the quality of life of patients and the continuation of oncological therapy.

Introduction:Genodermatoses associated with malignant tumors constitute a diagnostically important group of dermatological diseases. One of them is the Birt-Hogg-Dube syndrome, characterized by numerous fibrofolliculomas, trichodiscomas, (benign nodules originating from hair follicles), lung cysts and an increased risk of kidney cancer. Case report: A 81-year-old man was admitted to our clinic with erythematous-edematous, bullous and erosive skin lesions located on his trunk and limbs. During hospitalization, bullous pemphigoid and two types of basal cell carcinoma were diagnosed. Additionally, attention was paid to the presence of numerous flesh-colored papules on the surface of the face, neck and ears, corresponding to fibrofolliculoma in the histopathological examination. An in-depth medical history and detailed imaging diagnostics allowed the patient to be diagnosed with the Birt-Hogg-Dubé syndrome. Conclusions: Characteristic skin lesions and coexisting extra-cutaneous symptoms in Birt-Hogg-Dube syndrome allow early identification of patients at increased risk of kidney cancer. We describe the first case of Birt-Hogg-Dube syndrome associated with bullous pemphigoid and basal cell carcinoma.